Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8058280 | MYOVANT SCIENCES | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
Jan, 2025
(9 months from now) | |
US7300935 | MYOVANT SCIENCES | Thienopyrimidine compounds and use thereof |
Jan, 2025
(9 months from now) | |
US11795178 | MYOVANT SCIENCES | Compositions of thienopyrimidine derivatives |
Sep, 2033
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8735401 | MYOVANT SCIENCES | Thienopyrimidine compounds and use thereof |
Feb, 2024
(a month ago) | |
US10350170 | MYOVANT SCIENCES | Solid preparation |
Feb, 2036
(11 years from now) | |
US10449191 | MYOVANT SCIENCES | Treatment of prostate cancer |
Sep, 2037
(13 years from now) | |
US11583526 | MYOVANT SCIENCES | Treatment of prostate cancer |
Sep, 2037
(13 years from now) | |
US10786501 | MYOVANT SCIENCES | Treatment of prostate cancer |
Sep, 2037
(13 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 18, 2025 |
NCE-1 date: 2024-12-18
Market Authorisation Date: 18 December, 2020
Treatment: Treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent; Treatment of adult patients with advanced prostate cancer
Dosage: TABLET;ORAL